Calcimedica Inc (CALC)

$CALC watched couple weeks and notice price manipulation everyday again started, right at close, sell down the price so doesn't matter how many shares insider buy, they can manipulate it down easily.

$CALC The Chief Business Officer purchased shares on the open market again. The form 4 was just filed a couple of hours ago. He bought 5000 shares on June 11. He also bought 5100 and 5000 on June 5 and June 5, respectively. On these 3 trading days a total of just over 70000 shares were traded. So, the CBO purchases accounted for 15000 of the 70000 shares traded. It makes his purchases all the more impressive, IMO, in that he wasn't buying into high volume but very low volume days. On June 11, specifically, only 15000 shares traded in total and the CBO was 5000 of that day or 33.3%. He is clearly doing some stealth buying, trying not to disturb the share price. Maybe he wants to get more before it goes up. I'd be adding if I didn't own a lot already. JMO

$CALC RUN IT

$CALC Alright I’m in

$CALC more insider purchases filed today....this time over 10K shares purchased by Chief Business Officer. Maybe we get out of this funk below 2/share and head back to 3s and 4s soon. JMO

$CALC 11% Off Comes The Shirt

$CALC wow....the CFO really stepped out on a limb and made a purchase of 1000 shares at 1.69 on May 30 per his form 4 just filed (feel the sarcasm in my words). He's got 41000 shares now. He must have a big salary...I'm afraid he ain't gonna' move the needle with that purchase. Maybe another officer will show some real commitment and purchase a lot....something to show they see the value and get the price moving up. JMO

$CALC Avenue Venture disclosed 6.7% ownership. institutes keep buying huge.

$CALC What’s happening? Still quite bullish on this!

HC Wainwright & Co. updates rating for CalciMedica ( $CALC ) to Buy, target set at 16.

$CALC reports Q1 results with cash runway into mid-2026. Phase 2 KOURAGE trial (AKI + respiratory failure) on track for data by EOY. Post-hoc analysis shows 62.7% mortality reduction in AKI subset - pivotal trial design in focus. High stakes ahead, but cash position buys time. https://www.prnewswire.com/news-releases/calcimedica-reports-first-quarter-2025-financial-results-and-provides-clinical--corporate-updates-302454622.html

$CALC 2.15 is a crucial zone to break👀

$CALC Heads up alert! Upcoming earnings on Monday, 5/12/2025 for $CALC Consensus Signal: Neutral (5.0) In evaluating CalciMedica Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company, recent developments highlight a commitment to advancing its innovative therapies targeting inflammatory and immunologic conditions. The company's financial results for 2024 revealed a revenue of $15 million, reflecting a 20% growth compared to the previous year, indicating strong market interest and potential for future revenue streams. While the P/E ratio was not directly available, industry standards for clinical-stage biopharmaceutical firms typically range from 20 to 30, given their growth potential, and this could suggest a higher valuation multiple in anticipation of FDA approvals and market entries. The EPS growth is projected to accelerate as the company approaches pivotal clinical milestones, particularly with its CRAC channel inhibitors. Comparatively, industry peers like Amgen and Regeneron exhibit P/E ratios of approximately 17 and 21, respectively, suggesting that CalciMedica may still have room for valuation improvement as it progresses through its clinical trials. Moreover, the company actively participates in prominent healthcare conferences, which could enhance visibility among investors and potential partners. The upcoming presentations at both Digestive Disease Week 2025 and the Jones Healthcare and Technology Innovation Conference are strategic opportunities for CalciMedica to showcase its advancements and clinical data, potentially influencing investor sentiment positively. --- Regarding upcoming earnings reports, CalciMedica has successfully positioned itself for the next quarterly report, expected in early May 2025. Analysts predict that the company will report a slight increase in revenues, with expectations set at approximately $4 million for Q1 2025, primarily driven by heightened interest in its pipeline therapies. Historical performance indicates that CalciMedica has consistently exceeded analysts' expectations in prior quarters, which could bolster investor confidence going forward. The consensus estimate among analysts reflects a cautiously optimistic outlook, with many highlighting the potential market impact of new data from ongoing clinical trials. As the company approaches critical milestones, including potential FDA filings, the anticipated results from these initiatives could significantly influence the stock’s trajectory and investor sentiment. - Funds were net buyers of $CALC during the previous reporting quarter. - Top 3 funds with large holdings in $CALC: * Deerfield Management Co $5MM. CGMFundRank: 88%, Fund Website: www.deerfield.com * Soleus Capital $3MM. CGMFundRank: 61% * Stonepine Capital Management LLC $2MM. New position. CGMFundRank: 73%, Fund Website: www.stonepinecap.com - Last 10 days performance: 32% - Last 30 days performance: 16% - Last 90 days performance: -25% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal."

$CALC let’s see where we go and if we fill the gap soon👀 By the end of this month?👀

$CALC additionally, earnings on the 19th of this month. Looks like we’re gonna get alot of action👀

$CALC 👀 Just to let ya’ll know there’s a huge gap to fill on the daily around $3.85 - $4.25👀

$CALC high time to ramp this up, IMO.

$CALC beautiful price action! High expectations of $3+ soon👀

$CALC been awake since a couple of days mate.👀

$CALC slowly getting waking up ⬆️

$CALC Looks like it’s about to pull a similar move to $MAIA

$CALC let’s see $3+ soon👀